Search

Li, L., L. Zhang, X. Zhang, Q. Yan, Y. A. Minamishima, A. F. Olumi, M. Mao, S. Bartz, and W. G. Kaelin Jr. 2007. Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen With Type 2A and Type 2B VHL Mutations.

Li, W., C. L. Wu, P. G. Febbo, and A. F. Olumi. 2007. Stromally Expressed C-Jun Regulates Proliferation of Prostate Epithelial Cells.

Pedrosa, I., M. R. Sun, M. Spencer, E. M. Genega, A. F. Olumi, W. C. Dewolf, and N. M. Rofsky. 2008. MR Imaging of Renal Masses: Correlation With Findings at Surgery and Pathologic Analysis.

Dong, F., C. Wang, A. B. Farris, S. Wu, H. Lee, A. F. Olumi, W. S. McDougal, R. H. Young, and C. L. Wu. 2012. Impact on the Clinical Outcome of Prostate Cancer by the 2005 International Society of Urological Pathology Modified Gleason Grading System.

Preston, M. A., K. M. Wilson, S. C. Markt, R. Ge, C. Morash, M. J. Stampfer, M. Loda, E. Giovannucci, L. A. Mucci, and A. F. Olumi. 2014. 5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer.

Yun, H., J. Xie, A. F. Olumi, R. Ghosh, and A. P. Kumar. 2015. Activation of AKR1C1/ERβ Induces Apoptosis by Downregulation of C-FLIP in Prostate Cancer Cells: A Prospective Therapeutic Opportunity.

Frendl, D. M., and A. F. Olumi. 2017. Understanding Temporal Trends in Medical Costs Associated With Progression to Metastatic Prostate Cancer.

Rodin, D., M. Drumm, R. Clayman, D. L. Buscariollo, S. Galland-Girodet, A. Eidelman, A. S. Feldman, et al. 2017. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Single-Institution Experience.

Wang, Z., X. Xiao, R. Ge, J. Li, C. W. Johnson, C. Rassoulian, and A. F. Olumi. 2017. Metformin Inhibits the Proliferation of Benign Prostatic Epithelial Cells.

Burns, R. B., A. F. Olumi, D. K. Owens, and G. W. Smetana. 2019. Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.